Pfizer-Astra Deal Will Get Done
Cost-cutting, tax opportunities, and oncology synergies are motivating factors for Pfizer, and the firms will likely agree to merge, says Morningstar's Damien Conover.
Cost-cutting, tax opportunities, and oncology synergies are motivating factors for Pfizer, and the firms will likely agree to merge, says Morningstar's Damien Conover.
Damian Conover: Pfizer and AstraZeneca confirmed that they are in talks to merge, and while Pfizer offered close to $77 per share for AstraZeneca, AstraZeneca rejected the offer saying that the deal undervalued the full potential of the company.
We think the deal will likely get done, and we think there are three motivating factors for Pfizer. One is cost-cutting. Pfizer can cut a lot a costs from AstraZeneca. Second, there is tax opportunity with this acquisition and that Pfizer could lower its tax rate. And then third, the combination of the two companies really gives Pfizer a strong entrenchment in oncology, and this is a key therapeutic area were Pfizer wants to be in the future.
One important consideration for both Pfizer and AstraZeneca shareholders is the dividend, post the potential merger. As a lot of investors recall following the Wyeth transaction, Pfizer dramatically cut their dividend. We think that Pfizer's strategy and capacity constraints will more likely keep the dividend in place, but that is one area of concern for investors going in to a potential merger.
The next steps are that we think over the next 30 days, there'll be some more announcements. It could take a little bit longer for both sides to agree on the correct price, but we do think this deal will likely complete.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals
and individual investors. These products and services are usually sold through
license agreements or subscriptions. Our investment management business generates
asset-based fees, which are calculated as a percentage of assets under management.
We also sell both admissions and sponsorship packages for our investment conferences
and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.